

SENISCA Strengthens Senior Leadership Team

Exeter, UK — 18 May 2023: SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and target age-related disease, today announces the expansion of its leadership team with the appointment of Dr. Sarah Cole as Chief Operating Officer, Dr. Tim Schmidt as Chief Development Officer and Dr. Adam Clauss as VP Dermatology.

Dr. Sarah Cole, Chief Operating Officer

Sarah leads strategic development, communications and investor liaison activities at SENISCA. With over 20 years' experience at the forefront of early-stage research and the venture capital funding of biotech firms, Sarah has held senior research positions in global pharmaceutical and biotechnology companies including Takeda and Transine Therapeutics, as well as developing a successful career in life sciences investment at Takeda Ventures. Sarah is a recognised leader in strategic development, pipeline creation and the critical evaluation of business development opportunities, with a focus on the rapid evolution of early phase biotech. Sarah holds a PhD from the University of Cambridge.

Dr. Tim Schmidt, Chief Development Officer

Tim joins the SENISCA team from Oxford-based Sitryx Therapeutics and is responsible for devising and implementing the pre-clinical and early clinical research strategy at SENISCA. With nearly 20 years of drug development experience, Tim has held positions in both pharmaceutical companies including GSK and UCB and biotechnology companies including TxCell and Sitryx, where he successfully led the conception and implementation of translational and early clinical development strategies to progress several new therapeutic entities into Phase 1 and 2 clinical trials. Tim holds a PhD from University College London.

Dr. Adam Clauss, VP Dermatology

Adam has over 10 years of experience in the biopharmaceutical industry of which the latter part has been focused on the development and delivery of oligonucleotide drug candidates. He joins SENISCA from Bioglan where he served as Head of Development, and a member of the leadership team. He was responsible for GMP based drug and formulation development of semisolid therapy. Previously, Adam served as Senior Team Leader and Head of Regenerative Medicine at LEO Pharma, where he was responsible for drug development and delivery research efforts for their focus areas of gene therapy and oligonucleotide therapeutic approaches. Adam will oversee delivery of SENISCA's skin health partnership programme alongside dermatology-focused internal research programmes.

Kirsty Semple, CEO of SENISCA, commented:

"We are thrilled to have Sarah, Tim and Adam join the leadership team at such a critical growth stage for SENISCA. The extensive preclinical expertise that they bring will prove invaluable as we progress our work to develop novel therapeutics capable of reversing senescence to target the causes of age-related disease, not just the symptoms."

- Ends -

For more information

Jennie Jepperson
Executive Assistant, SENISCA
Jennie.Jepperson@senisca.com

For media

Consilium Strategic Communications
Chris Welsh, Evi Useh
welsh@consilium-comms.com

About SENISCA

SENISCA is an RNA therapeutics biotech spinout from the University of Exeter, founded in 2020. SENISCA is focused on modulating RNA biology to treat age-related disease. Underpinned by more than 15 years of world-leading research, SENISCA has identified an officially recognized, novel and druggable component of the cellular ageing (senescence) response, which can be specifically targeted in the context of multiple pharmacological and skin health indications.

The Company is developing a portfolio of proprietary senotherapeutics, including oligonucleotides and small molecules, that target cell senescence for cellular rejuvenation in the treatment of age-related disease. SENISCA's senotherapeutics specifically target the novel cellular pathway which causes cell rejuvenation and positively impacts markers of disease modification in patient-derived models. In line with the rapid evolution of the company, R & D activities are focused on IND data generation.

The Company's platform technology has broad applicability for multiple age-related diseases including those of the eye, lung, joint and brain. Many such diseases currently have no cure and existing treatments are only palliative, with varying success rates. These diseases are driven by senescence, are amenable to a local route of administration, and have high unmet clinical need. Targeting these specific diseases will streamline progress towards the clinic by avoiding potential pitfalls of systemic delivery.

SENISCA's novel senotherapeutics will be mined and commercialized through partnership or co-development models that will sit alongside internal programmes. If you would like to learn more about SENISCA, please contact Jennie Jepperson, Executive Assistant at SENISCA(Jennie.Jepperson@senisca.com).

